Roche Holding AG RHHBF
Set alert
As of Nov 2, 9:30 AM ET
- YTD
- +13.33%
- 1 year
- +59.66%
- Open
- 505.00
- Prev close
- 500.01
- Mkt cap
- 402.37B
- Vol
- 40
- Avg vol
- 95
- EPS
- 19.32
- P/E
- 26.14
More statistics
- Low
- 505.00
- High
- 505.00
- Earnings
- Jul 23, 2026
News
8 hours ago prnewswire.com
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
The new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to…
5 days ago seekingalpha.com
Roche: Valuation Leaves Limited Upside
Roche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well,…
5 days ago seekingalpha.com
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
Microsoft Corporation was the portfolio's top contributor during the quarter. Suncor Energy outperformed the Index during the quarter. KLA Corporation traded lower during the quarter.
1 week ago wsj.com
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology…
1 week ago reuters.com
Roche says divarasib cut risk of death 44% in lung cancer trial
Roche says divarasib cut risk of death 44% in lung cancer trial
1 week ago businesswire.com
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung…
1 week ago globenewswire.com
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational…
1 week ago businesswire.com
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III…
1 week ago globenewswire.com
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy…
1 week ago seekingalpha.com
Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
1 week ago zacks.com
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Roche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
1 week ago wsj.com
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Roche reiterated its full-year guidance and said it is prepared to launch its giredestrant breast-cancer pill later this year.
1 week ago reuters.com
Roche third quarter sales slightly beat expectations with growth across divisions
Roche third quarter sales slightly beat expectations with growth across divisions
1 week ago reuters.com
Roche says experimental MS pill cuts relapses by 55% in late-stage trials
Roche says experimental MS pill cuts relapses by 55% in late-stage trials
2 weeks ago wsj.com
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
The Swiss drugmaker will assume responsibility for outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
2 weeks ago reuters.com
Roche to unveil lung, breast cancer data at ESMO 2026
Roche to unveil lung, breast cancer data at ESMO 2026
2 weeks ago zacks.com
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
2 weeks ago zacks.com
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
2 weeks ago zacks.com
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
2 weeks ago reuters.com
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
-
3 weeks ago benzinga.com
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of…
-
1 month ago benzinga.com
Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney…
-
4 months ago benzinga.com
Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential…
-
1 year ago benzinga.com
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday